Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Congenital Adrenal Hyperplasia Market Expected to Grow Between 2025 And 2029?
The market for congenital adrenal hyperplasia has experienced robust growth in the past few years. It is projected to increase from $0.47 billion in 2024 to $0.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. This surge in the market size over the historic period is linked to factors such as the rising incidence of congenital adrenal hyperplasia, wider acceptance of corticosteroid therapies, an uptick in healthcare spending, a heightened emphasis on pediatric care, and enhanced government initiatives and reimbursement policies.
The market size for congenital adrenal hyperplasia is likely to experience firm expansion in the following years, ballooning to$0.65 billion by 2029″ with a 6.9% Compound Annual Growth Rate (CAGR). The boosting factors for this projected growth within the forecast timeframe include an increased demand for customized medicine, a rising number of genetic disorders, escalated focus on research for treating congenital adrenal hyperplasia, growth in healthcare investments, and an expanding use of telehealth in managing congenital adrenal hyperplasia. Some key trends to note for the forecast period are developments in healthcare infrastructure, progress in molecular diagnostic techniques, advancements in creating enzyme replacement therapies, maturation in long-acting corticosteroid formulation technologies, and improvements in genetic testing.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21157&type=smp
Which Factors and External Forces Are Driving Demand in the Congenital Adrenal Hyperplasia Market?
The growth of the congenital adrenal hyperplasia market is expected to be fueled by the increasing demand for gene therapy. Gene therapy refers to a medical strategy that involves altering or manipulating an individual’s genes to prevent or cure illnesses. The increased demand for gene therapy can be traced back to developments in genetic studies and biotechnology, which have facilitated more accurate and specific treatments for genetic disorders, cancers, and other long-term diseases. Opportunities for targeted genetic interventions are provided through gene therapy’s emphasis on the congenital adrenal hyperplasia (CAH) disorder, which is caused by alterations in the genes involved in adrenal hormone production. These interventions aim to correct genetic defects and restore normal hormone activity. For example, per the American Society of Gene and Cell Therapy (ASGCT), a US-based professional association, 1,023 gene therapies were being developed for rare diseases, with eight of the top 10 being oncological, as of April 2024. The initiation of 76 gene therapy trials in the second quarter of 2024, which represented a 25% increase from the previous quarter, suggests that the growing demand for gene therapy is contributing to the expansion of the congenital adrenal hyperplasia market.
Which Segments in the Congenital Adrenal Hyperplasia Offer the Most Growth?
The congenital adrenal hyperplasiamarket covered in this report is segmented –
1) By Type: Classic Congenital Adrenal Hyperplasia; Non-Classic Congenital Adrenal Hyperplasia
2) By Treatment And Diagnosis: Diagnosis; Treatment
3) By End-Use: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutes
Subsegments:
1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia; Simple Virilizing Classic Congenital Adrenal Hyperplasia
2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia; Mild Non-Classic Congenital Adrenal Hyperplasia
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21157&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Congenital Adrenal Hyperplasia Market?# Market?
North America was the largest region in the congenital adrenal hyperplasia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theCongenital Adrenal Hyperplasia Market’s Growth?
Leading firms in the congenital adrenal hyperplasia market are turning their attention towards the creation of innovative therapies like CRF1 receptor antagonists. These are set to control cortisol production and decrease the excessive adrenal androgen. The CRF1 receptor antagonist is a type of medication that inhibits the corticotropin-releasing factor 1 (CRF1) receptor, controlling the body’s stress response and lessening adrenal androgen overproduction, often seen in condiciones like congenital adrenal hyperplasia. Neurocrine Biosciences, Inc., an American biopharmaceutical company, for example, gained FDA approval in December 2024 for crenessity (crinecerfont), marking the first fresh treatment for congenital adrenal hyperplasia (CAH) in seven decades. This oral drug functions as an exclusive antagonist of corticotropin-releasing factor type 1 receptors, managing excessive adrenocorticotropic hormone (ACTH) and adrenal androgens and permitting lower glucocorticoid doses. The approval relied on findings from the CAHtalyst Phase 3 tests, revealing substantial effectiveness in decreasing androgen levels. Crenessity is set to be accessible shortly, signifying a considerable stride in the management of CAH.
View the full report here:
What Are the Key Elements That Define the Congenital Adrenal Hyperplasia Market?
Congenital adrenal hyperplasia refers to a group of inherited disorders affecting adrenal gland function due to enzyme deficiencies, primarily 21-hydroxylase. Congenital adrenal hyperplasia is managed through hormone replacement therapy to normalize cortisol and aldosterone levels, suppress excess androgen production, and address associated symptoms such as electrolyte imbalance and abnormal physical development.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21157
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model